Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from
clinical trials involving investigational compounds; Gilead's ability to initiate
clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug
applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from
clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks
identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
The team's next goal is to
identify a prospective
clinical application, Morgan said.
«This collaborative multi-disciplinary effort
identifies «mitochondrial genome integrity» as a vital readout in assessing the proficiency of patient - derived regenerative products destined for
clinical applications,» adds study co-author Andre Terzic, M.D., Ph.D., Director, Mayo Clinic Center for Regenerative Medicine.
In order to dissect these defects, we utilize a unique approach including deep assessment of patient phenotype,
clinical genetic testing to
identify underlying genetic contributions to these features, and the
application of combinatorial functional omics (transcriptome, metabolome, etc.) to uncover the pathological cellular states that result from these genetic changes.
We use multidisciplinary approaches to
identify and characterize genes which cause susceptibility to inherited cancer syndromes, to determine their role in sporadic carcinogenesis and to perform molecular epidemiologic analyses as they relate to
clinical applications.
Other
applications include designing
clinical trials to
identify at - risk populations for adverse drug reactions.
We include guidelines for performing resting state research on
clinical populations, outline the different areas for
clinical application, and
identify important barriers to be addressed to facilitate the translation of resting state fcMRI into the
clinical realm.
Although
applications involving use of deidentified human tissue were considered nonclinical
applications in this analysis, it is possible that the definition of
clinical research used by Williams
identified a different subset of
applications than were analyzed, even in the specific categories segregated in the current study.
Through interactions with its sister groups in the Bench to Bassinet program, the CvDC will
identify and pursue those basic discoveries in cardiac regulatory networks with the greatest potential to translate to
clinical applications for treatment and prevention.
The job responsibilities of a
clinical support specialist includes providing product training especially in installation, operation, and maintenance of
clinical products, giving presentations on
clinical product
applications, demo of product,
identifying customer requirements, educating customers and sales staff on the use of product, and providing inputs in sales program.
Educator: Developed and presented presentations on three separate topics to a national multi-disciplinary audience:
Clinical Information Systems Implementation, outlining weaknesses and strengths in the process; development of a Network level Informatics Office and DataMart,
identifying the synchronized plan to develop the office and address Network - wide weaknesses in performance management; and the benefits of utilizing the VistaWeb
application in enhancing the overall continuum of care for the Veteran.
Identified and resolved
clinical software documentation issues using various software
applications.
The manual guides
clinical application of Gottman Method Couples Therapy to help couples strengthen: • The Friendship System — the foundation for intimacy, passion, and good sex • The Conflict System — the basis for helping couples
identify and address solvable problems, and understand and manage irresolvable differences • The Shared Meaning System — the existential foundation of the relationship that helps couples discover their shared purpose for building a life together
Identify and describe the
application of a fidelity framework to studies addressing the
clinical benefit of supervision.
Research with men and women in long - term relationships who self -
identify as having optimal sexual experiences will be reviewed and their
clinical applications highlighted.